April 14th 2025
Vitrakvi (larotrectinib) was first granted accelerated approval by FDA in November 2018.
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Cambrex Invests in Generic API Development and Manufacturing Capabilities at its Milan Site
October 12th 2017Investments include the installation of development and analytical equipment to support the development of highly potent APIs as well as a new 2800-liter hydrogenator and 1500-mm diameter centrifuge for increased flexibility and capacity within the manufacturing plant.
Starting Early is Key to De-Risking Drug Development
October 2nd 2017The pharmaceutical industry is under tremendous pressure to make drug development faster and cheaper. Applying the right formulation strategy using structured and rigorous science can help avoid costly failures and re-starts, but it’s important to start from an early stage.
The Real Complexity of Excipient Composition
This article seeks to promote dialogue among stakeholders to facilitate consensus regarding requirements for excipients.
Six Sigma and the Path to Quality
October 2nd 2017Lawrence Yu, deputy director of the Office of Pharmaceutical Quality (OPQ), Center for Drug Evaluation and Research (CDER), and his FDA colleague, Michael Kopcha highlight the importance of Six Sigma approaches to continuous improvement in the pharmaceutical industry.